Keyphrases
Acute Lymphoblastic Leukemia
7%
Acute Myeloid Leukemia
11%
Adverse Events
7%
B Cell Receptor
10%
B-cell Malignancies
5%
B-cell Receptor Signaling
11%
Bone Marrow
5%
Bruton Tyrosine Kinase Inhibitor
8%
C-X-C Chemokine Receptor Type 4 (CXCR4)
8%
Chemoimmunotherapy
8%
Chemotherapy
6%
Chronic Lymphocytic Leukemia
96%
Chronic Lymphocytic Leukemia Cells
19%
Chronic Myeloid Leukemia
7%
Complete Remission
11%
Complete Response
6%
Cyclophosphamide
11%
Dasatinib
6%
Decitabine
6%
Del17p
6%
Fludarabine
12%
High Risk
7%
Ibrutinib
49%
Leukemia Cells
5%
Leukemia Patients
7%
Microenvironment
10%
Minimal Residual Disease
5%
Nave
6%
Newly Diagnosed
8%
Nurse-like Cells
5%
Older Patients
6%
Overall Response Rate
6%
Overall Survival
12%
Phase II Study
16%
Phase II Trial
7%
Progression-free Survival
9%
Relapsed or Refractory
17%
Relapsed or Refractory Acute Myeloid Leukemia
7%
Rituximab
18%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
12%
Acute Myeloid Leukemia
11%
Adverse Event
8%
B Cell
18%
B Lymphocyte Receptor
20%
B-Cell Chronic Lymphocytic Leukemia
100%
Bruton Tyrosine Kinase
6%
Bruton Tyrosine Kinase Inhibitor
10%
Cancer
8%
Chemoimmunotherapy
5%
Chemokine Receptor CXCR4
7%
Chronic Lymphocytic Leukemia
7%
Chronic Myelogenous Leukemia
5%
Cyclophosphamide
5%
Dasatinib
5%
Diseases
12%
Flow Cytometry
5%
Fludarabine
5%
Ibrutinib
53%
Leukemia
6%
Leukemia Cell
25%
Lymphocytic Lymphoma
12%
Malignant Neoplasm
7%
Minimal Residual Disease
9%
Neoplasm
7%
Overall Survival
13%
Philadelphia 1 Chromosome
5%
Progression Free Survival
12%
Rituximab
10%
Stromal Cell
8%
Targeted Therapy
8%
Venetoclax
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
12%
Acute Myeloid Leukemia
13%
Adverse Event
8%
B Lymphocyte Receptor
9%
Bruton Tyrosine Kinase Inhibitor
8%
Chemokine Receptor CXCR4
6%
Chemotherapy
10%
Chronic Lymphatic Leukemia
91%
Chronic Myeloid Leukemia
8%
Cyclophosphamide
12%
Cytarabine
5%
Dasatinib
7%
Decitabine
6%
Diseases
11%
Drug Resistance
5%
Fludarabine
13%
Ibrutinib
38%
Imatinib
6%
Leukemia
11%
Lymphocytic Lymphoma
9%
Malignant Neoplasm
7%
Minimal Residual Disease
8%
Neoplasm
5%
Overall Survival
16%
Progression Free Survival
11%
Protein Tyrosine Kinase Inhibitor
5%
Remission
16%
Rituximab
22%
Venetoclax
7%